JP2004519500A - セロトニン生成腫瘍の特異的細胞増殖抑制性治療に関するトリプトファン誘導体の使用法 - Google Patents
セロトニン生成腫瘍の特異的細胞増殖抑制性治療に関するトリプトファン誘導体の使用法 Download PDFInfo
- Publication number
- JP2004519500A JP2004519500A JP2002573016A JP2002573016A JP2004519500A JP 2004519500 A JP2004519500 A JP 2004519500A JP 2002573016 A JP2002573016 A JP 2002573016A JP 2002573016 A JP2002573016 A JP 2002573016A JP 2004519500 A JP2004519500 A JP 2004519500A
- Authority
- JP
- Japan
- Prior art keywords
- tryptophan
- serotonin
- htp
- producing
- hydroxytryptophan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 title claims abstract description 65
- 229940076279 serotonin Drugs 0.000 title claims abstract description 32
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical class C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 title claims abstract description 20
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 13
- 239000000824 cytostatic agent Substances 0.000 title claims abstract description 10
- 230000001085 cytostatic effect Effects 0.000 title claims abstract description 8
- 239000003814 drug Substances 0.000 claims abstract description 3
- VQSRKJZICBNQJG-UHFFFAOYSA-N 7-hydroxytryptophan Chemical compound C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1O VQSRKJZICBNQJG-UHFFFAOYSA-N 0.000 claims description 21
- 102000005506 Tryptophan Hydroxylase Human genes 0.000 claims description 16
- 108010031944 Tryptophan Hydroxylase Proteins 0.000 claims description 16
- 210000004027 cell Anatomy 0.000 claims description 12
- 210000004881 tumor cell Anatomy 0.000 claims description 10
- 102000003823 Aromatic-L-amino-acid decarboxylases Human genes 0.000 claims description 9
- 108090000121 Aromatic-L-amino-acid decarboxylases Proteins 0.000 claims description 9
- LXWHQTNFZDTKBH-UHFFFAOYSA-N 5,7-dihydroxytryptamine Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1O LXWHQTNFZDTKBH-UHFFFAOYSA-N 0.000 claims description 8
- 239000003053 toxin Substances 0.000 claims description 6
- 231100000765 toxin Toxicity 0.000 claims description 6
- 108700012359 toxins Proteins 0.000 claims description 6
- 201000006512 mast cell neoplasm Diseases 0.000 claims description 5
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 230000003211 malignant effect Effects 0.000 claims description 4
- 238000003786 synthesis reaction Methods 0.000 claims description 4
- NXANGIZFHQQBCC-VIFPVBQESA-N (2s)-2-amino-3-(6-hydroxy-1h-indol-3-yl)propanoic acid Chemical compound OC1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 NXANGIZFHQQBCC-VIFPVBQESA-N 0.000 claims description 3
- QSHLMQDRPXXYEE-UHFFFAOYSA-N 6-Hydroxytryptophan Natural products C1=CC(O)=C2C(CC(N)C(O)=O)=CNC2=C1 QSHLMQDRPXXYEE-UHFFFAOYSA-N 0.000 claims description 3
- NXANGIZFHQQBCC-UHFFFAOYSA-N DL-6-Hydroxy-tryptophan Natural products OC1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 NXANGIZFHQQBCC-UHFFFAOYSA-N 0.000 claims description 3
- 206010027476 Metastases Diseases 0.000 claims description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 3
- 210000004072 lung Anatomy 0.000 claims description 3
- 208000037841 lung tumor Diseases 0.000 claims description 3
- 201000011519 neuroendocrine tumor Diseases 0.000 claims description 3
- 210000000496 pancreas Anatomy 0.000 claims description 3
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 3
- SKOKLDQYOKPCPU-UHFFFAOYSA-N 3-(2-aminoethyl)-1h-indole-5,6-diol Chemical compound OC1=C(O)C=C2C(CCN)=CNC2=C1 SKOKLDQYOKPCPU-UHFFFAOYSA-N 0.000 claims description 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 230000010261 cell growth Effects 0.000 claims description 2
- QSHLMQDRPXXYEE-ZETCQYMHSA-N 4-hydroxy-L-tryptophan Chemical compound C1=CC(O)=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QSHLMQDRPXXYEE-ZETCQYMHSA-N 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003966 growth inhibitor Substances 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 210000001082 somatic cell Anatomy 0.000 claims 1
- 108010045269 tryptophyltryptophan Proteins 0.000 claims 1
- 235000021466 carotenoid Nutrition 0.000 abstract description 2
- 150000001747 carotenoids Chemical class 0.000 abstract description 2
- 231100000419 toxicity Toxicity 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- 208000002458 carcinoid tumor Diseases 0.000 description 5
- 210000001072 colon Anatomy 0.000 description 4
- 210000000664 rectum Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000012010 growth Effects 0.000 description 3
- NIGWMJHCCYYCSF-UHFFFAOYSA-N Fenclonine Chemical compound OC(=O)C(N)CC1=CC=C(Cl)C=C1 NIGWMJHCCYYCSF-UHFFFAOYSA-N 0.000 description 2
- 102000019208 Serotonin Plasma Membrane Transport Proteins Human genes 0.000 description 2
- 108010012996 Serotonin Plasma Membrane Transport Proteins Proteins 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- RETCYVKOCFWWTL-UHFFFAOYSA-N 3-(2-aminoethyl)-1h-indol-7-ol Chemical compound C1=CC=C2C(CCN)=CNC2=C1O RETCYVKOCFWWTL-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 101100221606 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS7 gene Proteins 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000003737 chromaffin cell Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10112882A DE10112882A1 (de) | 2001-03-15 | 2001-03-15 | Verwendung von Tryptophan-Derivaten zur spezifischen zytostatischen Behandlung von Serotonin-produzierenden Tumoren |
| PCT/DE2002/000959 WO2002074309A2 (de) | 2001-03-15 | 2002-03-15 | Verwendung von tryptophan-derivaten zur spezifischen zytostatischen behandlung von serotonin-produzierenden tumoren |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004519500A true JP2004519500A (ja) | 2004-07-02 |
| JP2004519500A5 JP2004519500A5 (https=) | 2005-12-22 |
Family
ID=7677818
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002573016A Withdrawn JP2004519500A (ja) | 2001-03-15 | 2002-03-15 | セロトニン生成腫瘍の特異的細胞増殖抑制性治療に関するトリプトファン誘導体の使用法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20040097576A1 (https=) |
| EP (1) | EP1368027B1 (https=) |
| JP (1) | JP2004519500A (https=) |
| AT (1) | ATE272400T1 (https=) |
| DE (2) | DE10112882A1 (https=) |
| ES (1) | ES2225789T3 (https=) |
| WO (1) | WO2002074309A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10043124A1 (de) * | 2000-08-31 | 2002-03-14 | Max Delbrueck Centrum | Verfahren zur Diagnostik von neuronalen Erkrankungen sowie zur Behandlung der defizienten primären Hämostase |
| GB2409048B (en) | 2003-12-09 | 2007-07-11 | Peter Steven Robertson | Electricity metering |
| US20060264178A1 (en) * | 2005-05-20 | 2006-11-23 | Noble Gayle L | Wireless diagnostic systems |
| CN109912489B (zh) * | 2019-03-08 | 2022-05-13 | 哈尔滨商业大学 | 非活化烯烃烷基化合成2,3-二氢色胺类化合物的方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2236876C3 (de) * | 1971-08-19 | 1981-02-12 | Ajinomoto Co., Inc., Tokio | N-Substituierte Aminocarbonsäuren und diese Verbindungen enthaltende Arzneimittel |
| US4183858A (en) * | 1977-07-01 | 1980-01-15 | Merrell Toraude Et Compagnie | α-Vinyl tryptophanes |
| DE3519687A1 (de) * | 1985-06-01 | 1986-12-04 | Veit Arend | Aminosaeuren enthaltendes arzneimittel |
| US5631281A (en) * | 1989-06-29 | 1997-05-20 | Warner-Lambert Company | N-substituted cycloalkyl and polycycloalkyl α-substituted Trp-Phe- and phenethylamine derivatives |
| US6124263A (en) * | 1998-11-16 | 2000-09-26 | Asta Medica Ag | Treatment of tumors by administration of growth hormone releasing compounds and their antagonists |
| WO2003030907A1 (en) * | 2001-10-09 | 2003-04-17 | Myriad Genetics, Inc. | Reverse-turn mimetics and composition and methods relating thereto |
-
2001
- 2001-03-15 DE DE10112882A patent/DE10112882A1/de not_active Withdrawn
-
2002
- 2002-03-15 JP JP2002573016A patent/JP2004519500A/ja not_active Withdrawn
- 2002-03-15 EP EP02732330A patent/EP1368027B1/de not_active Expired - Lifetime
- 2002-03-15 US US10/471,776 patent/US20040097576A1/en not_active Abandoned
- 2002-03-15 DE DE50200757T patent/DE50200757D1/de not_active Expired - Fee Related
- 2002-03-15 ES ES02732330T patent/ES2225789T3/es not_active Expired - Lifetime
- 2002-03-15 AT AT02732330T patent/ATE272400T1/de not_active IP Right Cessation
- 2002-03-15 WO PCT/DE2002/000959 patent/WO2002074309A2/de not_active Ceased
-
2007
- 2007-08-30 US US11/847,970 patent/US20070299128A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DE50200757D1 (de) | 2004-09-09 |
| ATE272400T1 (de) | 2004-08-15 |
| ES2225789T3 (es) | 2005-03-16 |
| US20070299128A1 (en) | 2007-12-27 |
| WO2002074309A2 (de) | 2002-09-26 |
| US20040097576A1 (en) | 2004-05-20 |
| EP1368027B1 (de) | 2004-08-04 |
| EP1368027A2 (de) | 2003-12-10 |
| DE10112882A1 (de) | 2002-09-19 |
| WO2002074309A3 (de) | 2002-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jung et al. | Melatonin in cancer management: progress and promise | |
| US8096419B2 (en) | Compound | |
| EP1529527A3 (en) | Valproic acid for a combination treatment of human cancers, tumor metastasis and minimal residual disease | |
| Chang et al. | Liposome encapsulation reduces cantharidin toxicity | |
| Rodríguez et al. | Heat shock protein 27 modulates autophagy and promotes cell survival after photodynamic therapy | |
| JP2008528701A (ja) | 腫瘍性疾患の治療又は予防に用いるためのニトロキシド類 | |
| Shang et al. | Effects of exogenous nitric oxide on oral squamous cell carcinoma: an in vitro study | |
| JP2001513110A (ja) | 腫瘍治療方法 | |
| Matsuno et al. | S-Benzylisothiourea derivatives as small-molecule inhibitors of indoleamine-2, 3-dioxygenase | |
| TWI862414B (zh) | 難治性癌症之預防或治療用之醫藥組合物 | |
| US20070299128A1 (en) | Use of Tryptophan Derivatives for the Specific Cytostatic Treatment of Serotonin-Producing Tumors | |
| Li et al. | Hyperbaric Oxygen‐Facilitated Cancer Treatment: A Minireview | |
| CN1199946C (zh) | 一种特异性吲哚类化合物及制备方法与其在治疗和预防癌症等疾病中的应用 | |
| CN109293588A (zh) | 一种具有ido1/tdo双靶点的小分子化合物及其制备方法与应用 | |
| US6867235B2 (en) | Helianthrone derivatives as anti-cancer agents | |
| WO1993023080A1 (en) | Targeted activated species cytotoxicity | |
| US12414931B1 (en) | Treatment of cancer using organoarsenicals | |
| Jain et al. | Progress in Synthetic Approaches and Pharmacological Applications of Melatonin and Its Derivatives: A Comprehensive Review | |
| Wijaya et al. | Locally Advanced and Metastatic Basal Cell Carcinoma: Update on Hedgehog Pathway Inhibitors | |
| JP2004519500A5 (https=) | ||
| JPWO2011078311A1 (ja) | 肝細胞癌治療のための抗腫瘍剤又は術後補助化学療法剤 | |
| CN110496128B (zh) | 利培酮或帕潘立酮在制备治疗弥漫性大b细胞淋巴瘤的药物中的应用 | |
| JP2004529642A5 (https=) | ||
| NZ538926A (en) | Medicament containing disorazoles and derivatives thereof for the treatment of benign and malignant tumoral diseases | |
| WO2008064596A1 (fr) | Composition pharmaceutique comprenant la protéine p43 pour le traitement de l'adénocarcinome gastrique |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040901 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040901 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20080320 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080512 |